OncoMatch/Clinical Trials/NCT06954831
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
Is NCT06954831 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for anatomic stage i breast cancer ajcc v8.
This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT involves a lumpectomy followed by breast radiation. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Traditionally, WBI has been given once daily over 5-6 weeks and then those at high-risk for recurrence receive additional radiation (boost) to the lumpectomy cavity daily over 4-8 days. This has now been replaced by moderate hypofractionated radiation. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Although moderate hypofractionated radiation therapy reduces the length of treatment from 6-7 weeks to 3-4 weeks, the length of treatment still remains a barrier for many patients. UF-WBI with CB delivers radiation to the whole breast and the surgical cavity at the same time over 5 daily treatments. Giving UF-WBI with CB may prevent recurrence and prolong survival as well as improve the quality of life in patients with stage I-III breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Prior therapy
Must have received: breast conserving surgery
Patients must have undergone breast conserving surgery. Re-excision for negative margins is allowed
Must have received: surgical staging of the axilla
Patients must have undergone surgical staging of the axilla (sentinel lymph node biopsy or axillary lymph node dissection)
Cannot have received: radiation therapy
Prior radiation to the region of the involved breast that in the opinion of the investigator would preclude breast irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope at Arcadia · Arcadia, California
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- City of Hope Antelope Valley · Lancaster, California
- City of Hope South Pasadena · South Pasadena, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify